Transplantation Infection
32
5
8
15
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
3.1%
1 terminated out of 32 trials
93.8%
+7.2% vs benchmark
19%
6 trials in Phase 3/4
33%
5 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (32)
High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Prevalence and Outcome of SARS-CoV-2 Infection & COVID-19 in Transplant Recipients: The COVITRA Study
Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.
Bacillus Clausii in Liver Transplantation
The Role of B Cells in Kidney Allograft Dysfunction
Description of Lung Transplant Patients With Microbiologically Documented Stenotrophomonas Maltophilia Pneumonia and Impact of Treatment on Outcome
Molecular Biological and Moleculargenetic Monitoring of Therapy After Kidney Transplantation
Intestinal Microbiome Dynamics in Solid Organ and Stem Cell Transplant Recipients
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
Improving Immunization Rates in Transplant Candidates Through the Use of a Health Information Technology Tool
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
CMV Infection and Immune Intervention After Transplantation
Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients